<!DOCTYPE html>
<html><head>
		<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
		<meta http-equiv="Content-Security-Policy" content="default-src 'none'; img-src data:; style-src 'unsafe-inline' data:">
		<title>Zotero Report</title>
		<link rel="stylesheet" type="text/css" href="data:text/css;base64,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">
		<link rel="stylesheet" type="text/css" media="screen,projection" href="data:text/css;base64,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">
		<link rel="stylesheet" type="text/css" media="print" href="data:text/css;base64,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">
	</head>
	<body>
		<ul class="report combineChildItems">
			<li id="item_FMR752LK" class="item conferencePaper">
			<h2>Periodic Chemotherapy Dose Schedule Optimization Using Genetic Algorithm</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Conference Paper</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Nadia Alam</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Munira Sultana</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>M. S. Alam</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>M. A. Al-Mamun</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>M. A. Hossain</td>
					</tr>
					<tr>
						<th class="editor">Editor</th>
						<td>Sigeru Omatu</td>
					</tr>
					<tr>
						<th class="editor">Editor</th>
						<td>José Neves</td>
					</tr>
					<tr>
						<th class="editor">Editor</th>
						<td>Juan M. Corchado Rodriguez</td>
					</tr>
					<tr>
						<th class="editor">Editor</th>
						<td>Juan F Paz Santana</td>
					</tr>
					<tr>
						<th class="editor">Editor</th>
						<td>Sara Rodríguez Gonzalez</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>This paper presents a design method for optimal cancer 
chemotherapy schedules using genetic algorithm (GA). The main objective 
of chemotherapy is to reduce the number of cancer cells or eradicate 
completely, if possible, after a predefined time with minimum toxic side
 effects which is difficult to achieve using conventional clinical 
methods due to narrow therapeutic indices of chemotherapy drugs. Three 
drug scheduling schemes are proposed where GA is used to optimize the 
doses and schedules by satisfying several treatment constraints. 
Finally, a clinically relevant dose scheme with periodic nature is 
proposed. Here Martin’s model is used to test the designed treatment 
schedules and observe cell population, drug concentration and toxicity 
during the treatment. The number of cancer cells is found zero at the 
end of the treatment for all three cases with acceptable toxicity. So 
the proposed design method clearly shows effectiveness in planning 
chemotherapy schedules.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2013</td>
					</tr>
					<tr>
					<th>Place</th>
						<td>Cham</td>
					</tr>
					<tr>
					<th>Publisher</th>
						<td>Springer International Publishing</td>
					</tr>
					<tr>
					<th>ISBN</th>
						<td>978-3-319-00551-5</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>503-511</td>
					</tr>
					<tr>
					<th>Proceedings Title</th>
						<td>Distributed Computing and Artificial Intelligence</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:50:56 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:50:56 PM</td>
					</tr>
				</tbody></table>
			</li>


			<li id="item_98HQXP2X" class="item journalArticle">
			<h2>Multi-objective optimal chemotherapy control model for cancer treatment</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>S. Algoul</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>M. S. Alam</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>M. A. Hossain</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>M. A. A. Majumder</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>This article presents an investigation into the development of
 a multi-objective optimal chemotherapy control model to reduce the 
number of cancer cells after a number of fixed treatment cycles with 
minimum side effects. Mathematical models for cancer chemotherapy are 
designed to predict the number of tumour cells and control the tumour 
growth during treatment. This requires an understanding of the system in
 the absence of treatment and a description of the effects of the 
treatment. In order to achieve multi-objective optimal control model, we
 used the proportional, integral and derivative (PID) and I-PD (modified
 PID with Integrator used as series) controllers based on Martin’s model
 for drug concentration. To the best of our knowledge, this is the first
 PID/IPD-based optimal chemotherapy control model used to investigate 
the cancer treatment. The proposed control schemes are designed based on
 the optimal solution of three objective functions, which include (i) 
maximising tumour cell killing, for (ii) minimum toxicity, and (iii) 
tolerable drug concentration. Multi-objective genetic algorithm (MOGA) 
is used to find suitable parameters of controllers that trade-off among 
design objectives considered in this work. The results of the different 
optimal scheduling patterns of the proposed models are presented and 
discussed through a set of experiments. Finally, the observations are 
compared with the existing models in order to demonstrate the merits and
 capabilities of the proposed multi-objective optimisation models. It is
 noted that the proposed model offers best performance as compared to 
any models reported earlier.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2011-01-01</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://doi.org/10.1007/s11517-010-0678-y">https://doi.org/10.1007/s11517-010-0678-y</a></td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>49</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>51-65</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Medical &amp; Biological Engineering &amp; Computing</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1007/s11517-010-0678-y">10.1007/s11517-010-0678-y</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>1</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>Medical &amp; Biological Engineering &amp; Computing</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>1741-0444</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>12/11/2025, 11:16:50 AM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>12/11/2025, 11:16:50 AM</td>
					</tr>
				</tbody></table>
			</li>


			<li id="item_7HMEVUHH" class="item journalArticle">
			<h2>Mathematical model for IL-2-based cancer immunotherapy</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Megan Dixon</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Tuan Anh Phan</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>J.C. Dallon</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Jianjun Paul Tian</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>A basic mathematical model for IL-2-based cancer immunotherapy
 is proposed and studied. Our analysis shows that the outcome of therapy
 is mainly determined by three parameters, the relative death rate of 
CD4+ T cells, the relative death rate of CD8+ T cells, and the dose of 
IL-2 treatment. Minimal equilibrium tumor size can be reached with a 
large dose of IL-2 in the case that CD4+ T cells die out. However, in 
cases where CD4+ and CD8+ T cells persist, the final tumor size is 
independent of the IL-2 dose and is given by the relative death rate of 
CD4+ T cells. Two groups of in silico clinical trials show some 
short-term behaviors of IL-2 treatment. IL-2 administration can slow the
 proliferation of CD4+ T cells, while high doses for a short period of 
time over several days transiently increase the population of CD8+ T 
cells during treatment before it recedes to its equilibrium. IL-2 
administration for a short period of time over many days suppresses the 
tumor population for a longer time before approaching its steady-state 
levels. This implies that intermittent administration of IL-2 may be a 
good strategy for controlling tumor size.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2024-06-01</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://www.sciencedirect.com/science/article/pii/S0025556424000476">https://www.sciencedirect.com/science/article/pii/S0025556424000476</a></td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>372</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>109187</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Mathematical Biosciences</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1016/j.mbs.2024.109187">10.1016/j.mbs.2024.109187</a></td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>Mathematical Biosciences</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>0025-5564</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:50:13 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:50:13 PM</td>
					</tr>
				</tbody></table>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>CD4 T cell</li>
					<li>CD8 T cell</li>
					<li>IL-2</li>
					<li>Immunotherapy</li>
				</ul>
			</li>


			<li id="item_BQICJT3W" class="item journalArticle">
			<h2>Pygad: An intuitive genetic algorithm python library</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Ahmed Fawzy Gad</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2023</td>
					</tr>
					<tr>
					<th>Extra</th>
						<td>Publisher: Springer</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>1–14</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Multimedia Tools and Applications</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:38:18 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:38:18 PM</td>
					</tr>
				</tbody></table>
			</li>


			<li id="item_AKHKTCYN" class="item journalArticle">
			<h2>Dynamically modeling the effective range of IL-2 dosage in the treatment of systemic lupus erythematosus</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Xin Gao</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Jing He</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Xiaolin Sun</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Fangting Li</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>Systemic lupus erythematosus (SLE) is a complex systemic 
autoimmune disease characterized by an overactive immune response to 
self-antigen. The overactivation of CD4+ Foxp3? conventional 
T&nbsp;cells (Tcons) and the inactivation of CD4+ CD25+ Foxp3+ 
regulatory T&nbsp;cells (Tregs) play important roles in the progression 
of SLE. Clinical trials showed that low-dose interleukin-2 (IL-2) is 
effective in treating SLE. Here, we developed a mathematical model 
involving Tcons, Tregs, natural killer (NK) cells, and IL-2 to simulate 
the dynamic processes involved in the treatment of SLE. We found an 
effective range of IL-2 dosage defined by the Tcon/Treg ratio in SLE 
treatment, termed the IL-2 dosage therapeutic window (IDTW). Our results
 showed that high levels of self-antigen result in a narrow IDTW and 
high post-treatment Tcon/Treg ratio. Furthermore, we proposed a 
classification method based on the ratio of pre-treatment Treg to CD4+ 
T&nbsp;cells to predict the treatment outcome of SLE patients.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2022-09-16</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://doi.org/10.1016/j.isci.2022.104911">https://doi.org/10.1016/j.isci.2022.104911</a></td>
					</tr>
					<tr>
					<th>Accessed</th>
						<td>11/13/2025, 7:00:00 PM</td>
					</tr>
					<tr>
					<th>Extra</th>
						<td>Publisher: Elsevier</td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>25</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>iScience</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1016/j.isci.2022.104911">10.1016/j.isci.2022.104911</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>9</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>2589-0042</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:51:50 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:51:50 PM</td>
					</tr>
				</tbody></table>
				<h3 class="notes">Notes:</h3>
				<ul class="notes">
					<li id="item_3FTK3IRH">
<div><p>doi: 10.1016/j.isci.2022.104911</p></div>
					</li>
				</ul>
			</li>


			<li id="item_QYVB62UY" class="item journalArticle">
			<h2>Standing Variations Modeling Captures Inter-Individual 
Heterogeneity in a Deterministic Model of Prostate Cancer Response to 
Combination Therapy</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Harsh V. Jain</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Inmaculada C. Sorribes</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Samuel K. Handelman</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Johnna Barnaby</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Trachette L. Jackson</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>Sipuleucel-T (Provenge) is the first live cell vaccine 
approved for advanced, hormonally refractive prostate cancer. However, 
survival benefit is modest and the optimal combination or schedule of 
sipuleucel-T with androgen depletion remains unknown. We employ a 
nonlinear dynamical systems approach to modeling the response of 
hormonally refractive prostate cancer to sipuleucel-T. Our mechanistic 
model incorporates the immune response to the cancer elicited by 
vaccination, and the effect of androgen depletion therapy. Because only a
 fraction of patients benefit from sipuleucel-T treatment, 
inter-individual heterogeneity is clearly crucial. Therefore, we 
introduce our novel approach, Standing Variations Modeling, which 
exploits inestimability of model parameters to capture heterogeneity in a
 deterministic model. We use data from mouse xenograft experiments to 
infer distributions on parameters critical to tumor growth and to the 
resultant immune response. Sampling model parameters from these 
distributions allows us to represent heterogeneity, both at the level of
 the tumor cells and the individual (mouse) being treated. Our model 
simulations explain the limited success of sipuleucel-T observed in 
practice, and predict an optimal combination regime that maximizes 
predicted efficacy. This approach will generalize to a range of emerging
 cancer immunotherapies.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2021</td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>13</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Cancers</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.3390/cancers13081872">10.3390/cancers13081872</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>8</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>2072-6694</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:53:04 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:53:04 PM</td>
					</tr>
				</tbody></table>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>ADT</li>
					<li>immunotherapy</li>
					<li>mathematical model</li>
					<li>prostate cancer</li>
					<li>provenge</li>
					<li>standing variations</li>
				</ul>
			</li>


			<li id="item_TYJA2B3L" class="item journalArticle">
			<h2>Optimal Treatment Strategy for a Tumor Model under Immune Suppression</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Kwang Su Kim</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Giphil Cho</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Il Hyo Jung</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>We propose a mathematical model describing tumor-immune 
interactions under immune suppression. These days evidences indicate 
that the immune suppression related to cancer contributes to its 
progression. The mathematical model for tumor-immune interactions would 
provide a new methodology for more sophisticated treatment options of 
cancer. To do this we have developed a system of 11 ordinary 
differential equations including the movement, interaction, and 
activation of NK cells, CD8+T-cells, CD4+T cells, regulatory T cells, 
and dendritic cells under the presence of tumor and cytokines and the 
immune interactions. In addition, we apply two control therapies, 
immunotherapy and chemotherapy to the model in order to control growth 
of tumor. Using optimal control theory and numerical simulations, we 
obtain appropriate treatment strategies according to the ratio of the 
cost for two therapies, which suggest an optimal timing of each 
administration for the two types of models, without and with 
immunosuppressive effects. These results mean that the immune 
suppression can have an influence on treatment strategies for cancer.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2014</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://onlinelibrary.wiley.com/doi/abs/10.1155/2014/206287">https://onlinelibrary.wiley.com/doi/abs/10.1155/2014/206287</a></td>
					</tr>
					<tr>
					<th>Extra</th>
						<td>_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1155/2014/206287</td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>2014</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>206287</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Computational and Mathematical Methods in Medicine</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/https://doi.org/10.1155/2014/206287">https://doi.org/10.1155/2014/206287</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>1</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>12/11/2025, 11:21:40 AM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>12/11/2025, 11:21:40 AM</td>
					</tr>
				</tbody></table>
			</li>


			<li id="item_IP5WAWHJ" class="item journalArticle">
			<h2>Modeling immunotherapy of the tumor – immune interaction</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Denise Kirschner</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>John Carl Panetta</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>A number of lines of evidence suggest that immunotherapy with 
the cytokine interleukin-2 (IL-2) may boost the immune system to fight 
tumors. CD4+ T cells, the cells that orchestrate the immune response, 
use these cytokines as signaling mechanisms for immune-response 
stimulation as well as lymphocyte stimulation, growth, and 
differentiation. Because tumor cells begin as ‘self’, the immune system 
may not respond in an effective way to eradicate them. Adoptive cellular
 immunotherapy can potentially restore or enhance these effects. We 
illustrate through mathematical modeling the dynamics between tumor 
cells, immune-effector cells, and IL-2. These efforts are able to 
explain both short tumor oscillations in tumor sizes as well as 
long-term tumor relapse. We then explore the effects of adoptive 
cellular immunotherapy on the model and describe under what 
circumstances the tumor can be eliminated.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>1998-09-01</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://doi.org/10.1007/s002850050127">https://doi.org/10.1007/s002850050127</a></td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>37</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>235-252</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Journal of Mathematical Biology</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1007/s002850050127">10.1007/s002850050127</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>3</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>Journal of Mathematical Biology</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>1432-1416</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:22:33 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:22:33 PM</td>
					</tr>
				</tbody></table>
			</li>


			<li id="item_XNHPXTIP" class="item journalArticle">
			<h2>Addressing current challenges in cancer immunotherapy with mathematical and computational modelling</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Anna Konstorum</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Anthony T. Vella</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Adam J. Adler</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Reinhard C. Laubenbacher</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2017-06-28</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://doi.org/10.1098/rsif.2017.0150">https://doi.org/10.1098/rsif.2017.0150</a></td>
					</tr>
					<tr>
					<th>Accessed</th>
						<td>11/13/2025, 7:00:00 PM</td>
					</tr>
					<tr>
					<th>Extra</th>
						<td>Publisher: Royal Society</td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>14</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>20170150</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Journal of The Royal Society Interface</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1098/rsif.2017.0150">10.1098/rsif.2017.0150</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>131</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>Journal of The Royal Society Interface</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:52:26 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:52:26 PM</td>
					</tr>
				</tbody></table>
				<h3 class="notes">Notes:</h3>
				<ul class="notes">
					<li id="item_YIWUX9L6">
<div><p>doi: 10.1098/rsif.2017.0150</p></div>
					</li>
				</ul>
			</li>


			<li id="item_VVBJK7T9" class="item journalArticle">
			<h2>The role of innate immune cells in the colorectal cancer tumor microenvironment and advances in anti-tumor therapy research</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Wenxuan Liu</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Tianrui Kuang</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Li Liu</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Wenhong Deng</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>Innate immune cells in the colorectal cancer microenvironment 
mainly include macrophages, neutrophils, natural killer cells, dendritic
 cells and bone marrow-derived suppressor cells. They play a pivotal 
role in tumor initiation and progression through the secretion of 
diverse cytokines, chemokines, and other factors that govern these 
processes. Colorectal cancer is a common malignancy of the 
gastrointestinal tract, and understanding the role of innate immune 
cells in the microenvironment of CRC may help to improve therapeutic 
approaches to CRC and increase the good prognosis. In this review, we 
comprehensively explore the pivotal role of innate immune cells in the 
initiation and progression of colorectal cancer (CRC), alongside an 
extensive evaluation of the current landscape of innate immune 
cell-based immunotherapies, thereby offering valuable insights for 
future research strategies and clinical trials.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2024</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1407449">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1407449</a></td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>Volume 15 - 2024</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Frontiers in Immunology</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.3389/fimmu.2024.1407449">10.3389/fimmu.2024.1407449</a></td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>1664-3224</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>12/10/2025, 10:01:26 AM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>12/10/2025, 10:01:26 AM</td>
					</tr>
				</tbody></table>
			</li>


			<li id="item_6SJBBALG" class="item journalArticle">
			<h2>Optimal control drug scheduling of cancer chemotherapy</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>R. B. Martin</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>This optimal control model of cancer chemotherapy constructs 
drug schedules that most effectively reduce the size of a tumour after a
 fixed period of treatment has elapsed. A constraint is imposed so that 
the tumour size must decrease at or faster than a specified rate. The 
system is solved using an established numerical solution technique known
 as control parametrization, and analytical gradients are constructed of
 all the constraints so that the resulting non-linear programming 
problem is solvable using currently available software. An interesting 
feature of the constraints on the rate of decrease of the tumour size is
 that the corresponding co-state functions are discontinuous in time. 
Numerical solutions suggest that the best way of reducing the tumour 
burden after a fixed period of treatment is to keep the rate of decrease
 of the tumour size to a minimum initially, and then give high-intensity
 treatment towards the end of the treatment period.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>1992</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://www.sciencedirect.com/science/article/pii/000510989290054J">https://www.sciencedirect.com/science/article/pii/000510989290054J</a></td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>28</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>1113-1123</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Automatica</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/https://doi.org/10.1016/0005-1098(92)90054-J">https://doi.org/10.1016/0005-1098(92)90054-J</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>6</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>0005-1098</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>12/11/2025, 11:16:19 AM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>12/11/2025, 11:16:19 AM</td>
					</tr>
				</tbody></table>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>Biomedical</li>
					<li>mathematical modeling</li>
					<li>non-linear programming</li>
					<li>optimal control</li>
				</ul>
			</li>


			<li id="item_SZC8HDYX" class="item journalArticle">
			<h2>A Memetic Algorithm for Multiple-Drug Cancer Chemotherapy Schedule Optimization</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>S. -M. Tse</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Y. Liang</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>K. -S. Leung</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>K. -H. Lee</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>T. S. -K. Mok</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>Feb. 2007</td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>37</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>84-91</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>IEEE Transactions on Systems, Man, and Cybernetics, Part B (Cybernetics)</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1109/TSMCB.2006.883265">10.1109/TSMCB.2006.883265</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>1</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>IEEE Transactions on Systems, Man, and Cybernetics, Part B (Cybernetics)</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>1941-0492</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:51:09 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:51:09 PM</td>
					</tr>
				</tbody></table>
			</li>


			<li id="item_SMK8R2BA" class="item journalArticle">
			<h2>Metaheuristics and Pontryagin’s minimum principle for optimal 
therapeutic protocols in cancer immunotherapy: a case study and methods 
comparison</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Sima Sarv Ahrabi</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Alireza Momenzadeh</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>In this paper, the performance appropriateness of 
population-based metaheuristics for immunotherapy protocols is 
investigated on a comparative basis while the goal is to stimulate the 
immune system to defend against cancer. For this purpose, genetic 
algorithm and particle swarm optimization are employed and compared with
 modern method of Pontryagin’s minimum principle (PMP). To this end, a 
well-known mathematical model of cell-based cancer immunotherapy is 
described and examined to formulate the optimal control problem in which
 the objective is the annihilation of tumour cells by using the minimum 
amount of cultured immune cells. In this regard, the main aims are: (i) 
to introduce a single-objective optimization problem and to design the 
considered metaheuristics in order to appropriately deal with it; (ii) 
to use the PMP in order to obtain the necessary conditions for 
optimality, i.e. the governing boundary value problem; (iii) to measure 
the results obtained by using the proposed metaheuristics against those 
results obtained by using an indirect approach called forward-backward 
sweep method; and finally (iv) to produce a set of optimal treatment 
strategies by formulating the problem in a bi-objective form and 
demonstrating its advantages over single-objective optimization problem.
 A set of obtained results conforms the performance capabilities of the 
considered metaheuristics.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2020-08-01</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://doi.org/10.1007/s00285-020-01525-7">https://doi.org/10.1007/s00285-020-01525-7</a></td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>81</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>691-723</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Journal of Mathematical Biology</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1007/s00285-020-01525-7">10.1007/s00285-020-01525-7</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>2</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>Journal of Mathematical Biology</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>1432-1416</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>12/4/2025, 12:06:40 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>12/4/2025, 12:06:40 PM</td>
					</tr>
				</tbody></table>
			</li>


			<li id="item_9LPQC5RA" class="item journalArticle">
			<h2>Triggering and enhancing chaos with a prescribed target Lyapunov exponent using optimized perturbations of minimum power</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>C. Y. Soong</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>W. T. Huang</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2007-03-13</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://link.aps.org/doi/10.1103/PhysRevE.75.036206">https://link.aps.org/doi/10.1103/PhysRevE.75.036206</a></td>
					</tr>
					<tr>
					<th>Extra</th>
						<td>Publisher: American Physical Society</td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>75</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>036206</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Physical Review E</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1103/PhysRevE.75.036206">10.1103/PhysRevE.75.036206</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>3</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>Phys. Rev. E</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:23:36 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:23:36 PM</td>
					</tr>
				</tbody></table>
			</li>


			<li id="item_6N7FFC4F" class="item journalArticle">
			<h2>Controlling chaos with weak periodic signals optimized by a genetic algorithm</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>C. Y. Soong</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>W. T. Huang</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>F. P. Lin</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>P. Y. Tzeng</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2004-07-23</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://link.aps.org/doi/10.1103/PhysRevE.70.016211">https://link.aps.org/doi/10.1103/PhysRevE.70.016211</a></td>
					</tr>
					<tr>
					<th>Extra</th>
						<td>Publisher: American Physical Society</td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>70</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>016211</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Physical Review E</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1103/PhysRevE.70.016211">10.1103/PhysRevE.70.016211</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>1</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>Phys. Rev. E</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:24:11 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:24:11 PM</td>
					</tr>
				</tbody></table>
			</li>


			<li id="item_SLE46GV3" class="item journalArticle">
			<h2>Ultimate dynamics of the Kirschner–Panetta model: Tumor eradication and related problems</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Konstantin E. Starkov</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Alexander P. Krishchenko</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>In this paper we consider the ultimate dynamics of the 
Kirschner–Panetta model which was created for studying the immune 
response to tumors under special types of immunotherapy. New ultimate 
upper bounds for compact invariant sets of this model are given, as well
 as sufficient conditions for the existence of a positively invariant 
polytope. We establish three types of conditions for the nonexistence of
 compact invariant sets in the domain of the tumor-cell population. Our 
main results are two types of conditions for global tumor elimination 
depending on the ratio between the proliferation rate of the immune 
cells and their mortality rate. These conditions are described in terms 
of simple algebraic inequalities imposed on model parameters and 
treatment parameters. Our theoretical studies of ultimate dynamics are 
complemented by numerical simulation results.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2017-10-17</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://www.sciencedirect.com/science/article/pii/S0375960117308058">https://www.sciencedirect.com/science/article/pii/S0375960117308058</a></td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>381</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>3409-3416</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Physics Letters A</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1016/j.physleta.2017.08.048">10.1016/j.physleta.2017.08.048</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>39</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>Physics Letters A</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>0375-9601</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:50:40 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:50:40 PM</td>
					</tr>
				</tbody></table>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>Compact invariant set</li>
					<li>Global stability</li>
					<li>Kirschner–Panetta tumor model</li>
					<li>Ultimate dynamics</li>
				</ul>
			</li>


			<li id="item_79Y9Q8FS" class="item journalArticle">
			<h2>Towards Predictive Computational Models of Oncolytic Virus Therapy: Basis for Experimental Validation and Model Selection</h2>
				<table>
					<tbody><tr>
						<th>Item Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Dominik Wodarz</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Natalia Komarova</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>Oncolytic viruses are viruses that specifically infect cancer 
cells and kill them, while leaving healthy cells largely intact. Their 
ability to spread through the tumor makes them an attractive therapy 
approach. While promising results have been observed in clinical trials,
 solid success remains elusive since we lack understanding of the basic 
principles that govern the dynamical interactions between the virus and 
the cancer. In this respect, computational models can help experimental 
research at optimizing treatment regimes. Although preliminary 
mathematical work has been performed, this suffers from the fact that 
individual models are largely arbitrary and based on biologically 
uncertain assumptions. Here, we present a general framework to study the
 dynamics of oncolytic viruses that is independent of uncertain and 
arbitrary mathematical formulations. We find two categories of dynamics,
 depending on the assumptions about spatial constraints that govern that
 spread of the virus from cell to cell. If infected cells are mixed 
among uninfected cells, there exists a viral replication rate threshold 
beyond which tumor control is the only outcome. On the other hand, if 
infected cells are clustered together (e.g. in a solid tumor), then we 
observe more complicated dynamics in which the outcome of therapy might 
go either way, depending on the initial number of cells and viruses. We 
fit our models to previously published experimental data and discuss 
aspects of model validation, selection, and experimental design. This 
framework can be used as a basis for model selection and validation in 
the context of future, more detailed experimental studies. It can 
further serve as the basis for future, more complex models that take 
into account other clinically relevant factors such as immune responses.</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2009-01-30</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://doi.org/10.1371/journal.pone.0004271">https://doi.org/10.1371/journal.pone.0004271</a></td>
					</tr>
					<tr>
					<th>Extra</th>
						<td>Publisher: Public Library of Science</td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>4</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>e4271</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>PLOS ONE</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1371/journal.pone.0004271">10.1371/journal.pone.0004271</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>1</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>PLOS ONE</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>11/13/2025, 11:24:45 PM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>11/13/2025, 11:24:45 PM</td>
					</tr>
				</tbody></table>
			</li>

		</ul>
	
</body></html>